MDT-AP-0831
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 102.60000000000001
- os_event
- false
- age_years
- 15
- sex
- F
- new_clusters
- C4
- umap1_2d
- 3.236731044
- umap2_2d
- 4.924134867
- umap1_3d
- 1.300840787
- umap2_3d
- -0.658400359
- umap3_3d
- -2.475696763
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.480
- E2F_TARGETS+0.440
- G2M_CHECKPOINT+0.400
- HEDGEHOG_SIGNALING+0.250
- WNT_BETA_CATENIN_SIGNALING+0.180
- MYOGENESIS+0.170
- MYC_TARGETS_V1+0.160
- ANGIOGENESIS+0.130
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.130
- SPERMATOGENESIS+0.130
Top 10 suppressed
- PROTEIN_SECRETION-0.440
- INTERFERON_GAMMA_RESPONSE-0.370
- INTERFERON_ALPHA_RESPONSE-0.360
- PANCREAS_BETA_CELLS-0.350
- UV_RESPONSE_DN-0.240
- ANDROGEN_RESPONSE-0.230
- TNFA_SIGNALING_VIA_NFKB-0.220
- ALLOGRAFT_REJECTION-0.210
- FATTY_ACID_METABOLISM-0.200
- KRAS_SIGNALING_UP-0.190
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD036_D.RNA-Seq | EPN | Supratentorial EPN | 0.824 |
| 2 | SRR8518126 | — | E | 0.815 |
| 3 | SRR12475126 | — | — | 0.805 |
| 4 | TCGA-77-8148-01A-11R-2247-07 | — | cohortSQ2 | 0.804 |
| 5 | SRR8613782 | — | E | 0.801 |
| 6 | C3L-00445 | — | cohortSQ2 | 0.799 |
| 7 | BS_C05FKR8X | EPN | Supratentorial EPN | 0.791 |
| 8 | SRR12475144 | — | — | 0.783 |
| 9 | BS_C05FKR8X | Supratentorial Ependymoma | — | 0.781 |
| 10 | TCGA-34-7107-01A-11R-1949-07 | — | cohortSQ2 | 0.781 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.480 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.440 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.400 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.250 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.180 | Inavolisib | — uncovered |
| MYOGENESIS | 0.170 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.160 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.130 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.130 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.130 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.120 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.110 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.110 | Idelalisib | — uncovered |
| HYPOXIA | 0.100 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.080 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.080 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.070 | Remibrutinib | — uncovered |
| COAGULATION | 0.060 | Binimetinib | — uncovered |
| APICAL_SURFACE | 0.050 | Temsirolimus | — uncovered |
| GLYCOLYSIS | 0.040 | Inavolisib | — uncovered |